Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice - PubMed (original) (raw)
Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice
A Fredriksson et al. J Neural Transm (Vienna). 2001.
Abstract
The antiparkinsonian effects of the uncompetitive NMDA antagonists, memantine, amantadine and MK-801, in combination with an acute subthreshold dose of L-Dopa (5 mg/kg) in drug-naive MPTP-treated mice or a suprathreshold dose (20 mg/kg) in L-Dopa tolerant MPTP-treated mice were investigated. In the former case, memantine (locomotion: 3 mg/kg; rearing: 1 mg/kg) and amantadine (locomotion and rearing: 10 mg/kg) injected 60 min before the subthreshold dose of L-Dopa (5 mg/kg), each induced an antiparkinsonian action in hypokinesic MPTP-treated mice that consisted of dose-specific, as opposed to dose-related, elevations of locomotion and rearing behaviour. At the same time, higher doses of memantine reduced further the rearing (10 and 30 mg/kg) and locomotor (30mg/kg) behaviour of the MPTP-treated mice. MK-801 plus L-Dopa elevated locomotion (0.1 mg/kg) but reduced rearing at the 0.3 mg/kg dose. In control, saline-treated mice, memantine (3, 10 and 30 mg/kg) and MK-801 (0.1 and 0.3 mg/kg) increased locomotor behaviour but decreased rearing behaviour, while amantadine produced no effects. Memantine increased locomotor (1 and 3 mg/kg, s.c.; 1 mg/kg dose restored activity) and rearing (0.3 and 3 mg/kg) activity in the L-Dopa tolerant MPTP-treated mice, whereas amantadine (3 and 10 mg/kg) restored both locomotor (30 mg/kg significantly increased locomotion but did not restore the activity level) and rearing (3 mg/kg only) activity. MK-801 (0.1 and 0.3 mg/kg, s.c.) also increased significantly locomotor activity of L-Dopa-tolerant MPTP mice although the antikinetic action was not reversed, thereby precluding a restorative effect of the compound. These results, demonstrating both a synergistic and a restorative effect of the NMDA antagonists in coadministration with L-Dopa, demonstrate a putative antiparkinson action by these compounds in a functional animal model that incorporates the "wearing-off" complications of L-Dopa administration in the disorder.
Similar articles
- Functional alteration by NMDA antagonist: effects of L-Dopa, neuroleptics drug and postnatal administration.
Fredriksson A, Archer T. Fredriksson A, et al. Amino Acids. 2002;23(1-3):111-32. doi: 10.1007/s00726-001-0117-3. Amino Acids. 2002. PMID: 12373526 - Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists.
Fredriksson A, Palomo T, Chase T, Archer T. Fredriksson A, et al. J Neural Transm (Vienna). 1999;106(3-4):283-300. doi: 10.1007/s007020050158. J Neural Transm (Vienna). 1999. PMID: 10392537 - Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice.
Fredriksson A, Palomo T, Archer T. Fredriksson A, et al. J Neural Transm (Vienna). 1999;106(9-10):889-909. doi: 10.1007/s007020050209. J Neural Transm (Vienna). 1999. PMID: 10599871 - Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration.
Fredriksson A, Archer T. Fredriksson A, et al. Behav Brain Res. 2003 Feb 17;139(1-2):31-46. doi: 10.1016/s0166-4328(02)00035-9. Behav Brain Res. 2003. PMID: 12642174 - Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.
Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G. Danysz W, et al. Neurosci Biobehav Rev. 1997 Jul;21(4):455-68. doi: 10.1016/s0149-7634(96)00037-1. Neurosci Biobehav Rev. 1997. PMID: 9195603 Review.
Cited by
- Breast cancer expresses functional NMDA receptors.
North WG, Gao G, Memoli VA, Pang RH, Lynch L. North WG, et al. Breast Cancer Res Treat. 2010 Jul;122(2):307-14. doi: 10.1007/s10549-009-0556-1. Epub 2009 Sep 26. Breast Cancer Res Treat. 2010. PMID: 19784770 Free PMC article. - An Experimental Study to Evaluate the Effect of Memantine in Animal Models of Anxiety in Swiss Albino Mice.
Bagewadi HG, Ak AK, Shivaramegowda RM. Bagewadi HG, et al. J Clin Diagn Res. 2015 Aug;9(8):FF01-5. doi: 10.7860/JCDR/2015/13233.6287. Epub 2015 Aug 1. J Clin Diagn Res. 2015. PMID: 26435964 Free PMC article. - Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
Duty S, Jenner P. Duty S, et al. Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x. Br J Pharmacol. 2011. PMID: 21486284 Free PMC article. Review. - Pharmacodynamics of memantine: an update.
Rammes G, Danysz W, Parsons CG. Rammes G, et al. Curr Neuropharmacol. 2008 Mar;6(1):55-78. doi: 10.2174/157015908783769671. Curr Neuropharmacol. 2008. PMID: 19305788 Free PMC article. - Estimation of and correction for finite motion sampling errors in small animal PET rigid motion correction.
Miranda A, Staelens S, Stroobants S, Verhaeghe J. Miranda A, et al. Med Biol Eng Comput. 2019 Feb;57(2):505-518. doi: 10.1007/s11517-018-1899-8. Epub 2018 Sep 22. Med Biol Eng Comput. 2019. PMID: 30242596 Free PMC article.
References
- J Neural Transm Gen Sect. 1994;97(3):197-209 - PubMed
- J Neural Transm Park Dis Dement Sect. 1994;7(2):123-32 - PubMed
- Pharmacol Toxicol. 1990 Oct;67(4):295-301 - PubMed
- Eur J Neurosci. 1996 Mar;8(3):446-54 - PubMed
- Eur J Pharmacol. 1986 Oct 7;129(3):339-45 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources